2510006D16Rik Activators
2510006D16Rik activators engage a variety of signaling pathways that converge to enhance the functional activity of the protein. Forskolin serves as a pivotal activator; by elevating intracellular cAMP levels, it activates PKA, which could phosphorylate substrates within 2510006D16Rik's signaling network, thus indirectly increasing its activity. 2510006D16Rik Activators is a classification for a set of chemicals known to initiate the activation of the 2510006D16Rik gene. The discovery and assessment of these activators typically begin with a high-throughput screening (HTS) strategy. This method involves testing large libraries of chemical compounds to find those that can affect gene expression. In the case of 2510006D16Rik activators, the screening relies on a reporter assay system, which integrates a measurable reporter gene, often encoding for a fluorescent or luminescent marker, under the control of the 2510006D16Rik gene promoter.
When a compound in the screening library interacts with and activates this promoter, it drives the expression of the reporter, resulting in a quantifiable signal. The intensity of this signal is directly proportional to the activation effect of the compound on the promoter. Compounds that cause a marked increase in signal are then selected for further validation. This primary screening stage is designed to effectively single out compounds that can upregulate the expression of the gene of interest, setting the stage for more in-depth analyses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several protein kinases, potentially reducing competitive signaling and allowing pathways involving 2510006D16Rik to be less hindered, potentially leading to an increased functional activity of 2510006D16Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may influence signaling pathways that include 2510006D16Rik, indirectly enhancing its activity by modulating related proteins or substrates in the pathway. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, which can activate calcium-dependent signaling pathways. These pathways may interact with those involving 2510006D16Rik, indirectly enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P interacts with its receptors to activate intracellular signaling pathways that could intersect with pathways involving 2510006D16Rik, potentially leading to its enhanced activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which can alter signaling cascades and potentially relieve inhibitory control on pathways that 2510006D16Rik is involved in, leading to its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could reduce competitive signaling pathways and potentially enhance those that 2510006D16Rik is part of, leading to an increase in its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as an ionophore for calcium, enhancing intracellular calcium signaling which may interact with pathways involving 2510006D16Rik, potentially enhancing its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
While a broad-spectrum kinase inhibitor, staurosporine could selectively enhance pathways where 2510006D16Rik is involved by inhibiting kinases that negatively regulate these pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast, another phosphodiesterase inhibitor, could increase levels of cGMP, which may influence signaling pathways that include 2510006D16Rik, leading to its indirect activation. | ||||||